Amphotericin B potentiates the activation of inducible nitric oxide synthase and causes nitric oxide-dependent mitochondrial dysfunction in cytokine-treated rodent astrocytes

Glia. 2001 Sep;35(3):180-8. doi: 10.1002/glia.1083.

Abstract

Because the neurotoxic effects of the antifungal drug amphotericin B (AMB) closely resemble those ascribed to the highly reactive gaseous free radical nitric oxide (NO), we investigated the effect of AMB on NO production in rodent astrocytes. AMB caused a dose-dependent increase of NO generation in interferon-gamma (IFN-gamma)-stimulated rat and mouse astrocytes, as well as in IFN-gamma + tumor necrosis factor-alpha (TNF-alpha)-activated rat astrocytoma cell line C6. Treatment of rat astrocytes with AMB markedly potentiated IFN-gamma-triggered expression of mRNA for iNOS, but not for its transcription factor IRF-1. The activation of transcription factor NF-kappaB was apparently required for AMB-induced iNOS mRNA expression, as the latter was abolished by NF-kappaB inhibitors: pyrrolidine dithiocarbamate and MG132. AMB-mediated enhancement of astrocyte NO production was partly dependent on endogenous IL-1, as shown by partial inhibition of AMB effect with IL-1 receptor antagonist. IFN-gamma + AMB treatment led to reduction of astrocyte mitochondrial respiration (measured by MTT assay) that has been completely reverted by selective iNOS inhibitor aminoguanidine. AMB toxicity toward IFN-gamma-stimulated astrocytes was dependent on both AMB and NO action, since AMB and NO-releasing substance SNP synergized in inducing astrocyte mitochondrial dysfunction. These results suggest that the enhancement of cytokine-induced iNOS activation in astrocytes and the subsequent release of high amounts of NO might be at least partly responsible for AMB neurotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / pharmacology*
  • Animals
  • Animals, Newborn
  • Antifungal Agents / pharmacology*
  • Astrocytes / drug effects*
  • Astrocytes / metabolism
  • Cell Respiration / drug effects
  • Cell Respiration / physiology
  • Central Nervous System Fungal Infections / drug therapy
  • DNA-Binding Proteins / genetics
  • Drug Interactions / physiology
  • Enzyme Inhibitors / pharmacology
  • Interferon Regulatory Factor-1
  • Interferon-gamma / pharmacology*
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / metabolism
  • Mice
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • NF-kappa B / genetics
  • Nerve Degeneration / chemically induced
  • Nerve Degeneration / metabolism
  • Nerve Degeneration / physiopathology
  • Neurotoxins / pharmacology
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase / genetics*
  • Phosphoproteins / genetics
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Rats
  • Sialoglycoproteins / pharmacology
  • Transcription, Genetic / drug effects
  • Transcription, Genetic / physiology
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antifungal Agents
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Il1rn protein, mouse
  • Interferon Regulatory Factor-1
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Irf1 protein, mouse
  • Irf1 protein, rat
  • NF-kappa B
  • Neurotoxins
  • Nitric Oxide Donors
  • Phosphoproteins
  • RNA, Messenger
  • Sialoglycoproteins
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • Amphotericin B
  • Interferon-gamma
  • Nitric Oxide Synthase